Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn's Program

The Japan Patent Office (JPO) has issued a Decision to Grant a Patent covering RHB-104 with a 2029 expiry date RedHill has initiated a long-term population pharmacokinetic study with RHB-104...
June 02, 2014 09:15 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

TEL-AVIV, Israel, June 2, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the...
May 22, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces FDA Clearance for Phase III Study With RHB-102 Planned to Commence in Q3/2014

FDA's clearance of RedHill's Investigational New Drug ("IND") amendment allows the initiation of a Phase III clinical study for a new undisclosed indication with RHB-1021, a proprietary,...
May 21, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014

TEL-AVIV, Israel, May 21, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and...
May 01, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014

TEL-AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and...
April 30, 2014 11:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Results for the First Quarter of 2014

Key financial highlights include: A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...
April 30, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014

RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory...
April 29, 2014 10:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014

TEL-AVIV, Israel, April 29, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
April 28, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014

TEL-AVIV, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...
April 24, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film

TEL-AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...